The use of individualized tumor response testing in treatment selection: Second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry

The use of individualized tumor response testing in treatment selection: Second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry

Show other versions (1)

Bibliographic Details
Main Authors:	Matutes, E, Bosanquet, A, Wade, R, Richards, S, Else, M, Catovsky, D
Format:	Journal article
Language:	English
Published:	2013

Similar Items

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.
by: Matutes, E, et al.
Published: (2013)

Quality of life in the LRF CLL4 trial.
by: Else, M, et al.
Published: (2005)

Prognostic factors in the UK LRF CLL4 trial
by: Oscier, D, et al.
Published: (2006)

The lack of survival differences in randomised trials in CLL may be related to the effect of second line therapies. A report from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2006)

Quality of life in the UK LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Else, M, et al.
Published: (2006)

Prognostic factors in the UK LRF CLL4 trial.
by: Oscier, D, et al.
Published: (2005)

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.
by: Oscier, D, et al.
Published: (2010)

Early results from LRF CLL4: A UK multicenter randomized trial
by: Catovsky, D, et al.
Published: (2005)

Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
by: Else, M, et al.
Published: (2012)

Comparison of oral and intravenous fludarabine in the LRF CLL4 trial.
by: Hillmen, P, et al.
Published: (2005)

Prognostic factors in the UK LRF CLL4 trial.
by: Oscier, D, et al.
Published: (2006)

Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2004)

Drug sensitivity by TRAC (DISC) assay as a prognostic factor for patient response in untreated CLL: Results from the UK LRF CLL4 trial.
by: Bosanquet, A, et al.
Published: (2006)

Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial.
by: Else, M, et al.
Published: (2008)

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
by: Catovsky, D, et al.
Published: (2007)

A comparison of oral and intravenous fludarabine in the LRF CLL4 trial (on behalf of the UKNCRI CLL trials group)
by: Hillmen, P, et al.
Published: (2006)

Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Catovsky, D, et al.
Published: (2006)

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
by: Dearden, C, et al.
Published: (2011)

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
by: Gonzalez, D, et al.
Published: (2011)

The combination of fludarabine and cyclophosphamide has a beneficial effect on the incidence of hemolytic anemia in chronic lymphocytic leukemia. Results from the UK LRF CLL4 trial
by: Dearden, C, et al.
Published: (2007)

Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
by: Lin, K, et al.
Published: (2012)

Preliminary results of the UK Medical Research Council trial in chronic lymphocytic leukaemia - CLL3
by: Catovsky, D, et al.
Published: (1998)

Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing.
by: Bosanquet, A, et al.
Published: (2009)

Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis.
by: Sellick, G, et al.
Published: (2008)

Incidence of hemolytic anemia after chemotherapy in the CLL4 trial. A possible protective role for fludarabine plus cyclophosphamide.
by: Catovsky, D, et al.
Published: (2004)

UK Medical Research Council CLL3 - A randomized trial of the addition of epirubicin to standard chlorambucil treatment.
by: Catovsky, D, et al.
Published: (2000)

Baseline characteristics associated with quality of life in CLL patients requiring therapy
by: Else, M, et al.
Published: (2007)

Do not treat all CLL patients with fludarabine
by: Bosanquet, A, et al.
Published: (1998)

Collaborative meta-analysis of randomised trials in chronic lymphocytic leukaemia (CLL)
by: Binet, J, et al.
Published: (1998)

High mortality of DiSC assay-resistant CLL patients treated with fludarabine.
by: Bosanquet, A, et al.
Published: (1998)

Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion
by: Gonzalez, D, et al.
Published: (2008)

Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults.
by: Catovsky, D, et al.
Published: (1989)

Final results of a randomized trial comparing autotransplant versus wait and watch in 222 patients with CLL in 1(st) or 2(nd) remission (EBMT CLL auto trial / GCLLSG CLL3R trial)
by: McClanahan, F, et al.
Published: (2010)

Gender as a prognostic factor in CLL. Biological pointers to the improved outcome of women.
by: Catovsky, D, et al.
Published: (2004)

isr-fctuc_lrf1_lrf2_cam_imu_carmen_dataset
by: Davim, Luis, et al.
Published: (2011)

Comparison of ZAP-70, IgVH gene mutational status and CD38 in CLL patients requiring therapy: Preliminary report from the UKCLL IV trial.
by: Orchard, J, et al.
Published: (2003)

The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia.
by: Dearden, C, et al.
Published: (2008)

Results of the randomised phase II NCRI arctic (attenuated dose rituximab with chemotherapy in CLL) trial of low dose rituximab in previously untreated CLL
by: Munir, T, et al.
Published: (2014)

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
by: Pettitt, A, et al.
Published: (2012)

Experiences in the design and implementation of phase II trials in CLL
by: Cohen Dena R, et al.
Published: (2011-12-01)